In vivo response monitoring of treatment with the epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in metastatic colorectal cancer: a single centre phase II study.
Phase of Trial: Phase II
Latest Information Update: 02 Jul 2018
At a glance
- Drugs Cetuximab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms REMOTUX
- 02 Jul 2018 Primary endpoint has been met. (predictive significance of DeltaSUV for ECR) as per results published in the British Journal of Cancer
- 02 Jul 2018 Results published in the British Journal of Cancer
- 09 Feb 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2009-013279-23).